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Background: One-third of breast cancers display amplifications of the ERBB2 gene encoding the HER2 kinase
receptor. Trastuzumab, a humanized antibody directed against an epitope on subdomain IV of the extracellular
domain of HER2 is used for therapy of HER2-overexpressing mammary tumors. However, many tumors are either
natively resistant or acquire resistance against Trastuzumab. Antibodies directed to different epitopes on the
extracellular domain of HER2 are promising candidates for replacement or combinatorial therapy. For example,
Pertuzumab that binds to subdomain II of HER2 extracellular domain and inhibits receptor dimerization is under
clinical trial. Alternative antibodies directed to novel HER2 epitopes may serve as additional tools for breast cancer
therapy. Our aim was to generate novel anti-HER2 monoclonal antibodies inhibiting the growth of breast cancer
cells, either alone or in combination with tumor necrosis factor-α (TNF-α).
Methods: Mice were immunized against SK-BR-3 cells and recombinant HER2 extracellular domain protein to
produce monoclonal antibodies. Anti-HER2 antibodies were characterized with breast cancer cell lines using
immunofluorescence, flow cytometry, immunoprecipitation, western blot techniques. Antibody epitopes were
localized using plasmids encoding recombinant HER2 protein variants. Antibodies, either alone or in combination
with TNF-α, were tested for their effects on breast cancer cell proliferation.
Results: We produced five new anti-HER2 monoclonal antibodies, all directed against conformational epitope or
epitopes restricted to the native form of the extracellular domain. When tested alone, some antibodies inhibited
modestly but significantly the growth of SK-BR-3, BT-474 and MDA-MB-361 cells displaying ERBB2 amplification.
They had no detectable effect on MCF-7 and T47D cells lacking ERBB2 amplification. When tested in combination
with TNF-α, antibodies acted synergistically on SK-BR-3 cells, but antagonistically on BT-474 cells. A representative
anti-HER2 antibody inhibited Akt and ERK1/2 phosphorylation leading to cyclin D1 accumulation and growth arrest
in SK-BR-3 cells, independently from TNF-α.
Conclusions: Novel antibodies against extracellular domain of HER2 may serve as potent anti-cancer bioactive
molecules. Cell-dependent synergy and antagonism between anti-HER2 antibodies and TNF-α provide evidence for
a complex interplay between HER2 and TNF-α signaling pathways. Such complexity may drastically affect the
outcome of HER2-directed therapeutic interventions.
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With a lifetime risk of ~12%, breast cancer is the most
common cancer in women [1]. Although the survival
rates of breast cancer patients are increasing due to the
recently developed therapeutic approaches, breast cancer
remains the most frequent cause of cancer-related death
in women [2]. More than 225,000 new cases of female-
breast cancer are estimated to occur in 2012, in the Uni-
ted States alone, and 40,000 female deaths are expected
as a result [3]. 25-30% of breast cancers display HER2
overexpression [4]. ERBB2 gene amplification that was
discovered in the early 1980s is the main cause of HER2
overexpression [5]. HER2 is a tyrosine kinase receptor
belonging to the ErbB/HER family that also includes epi-
dermal growth factor receptor (EGFR/HER1), ErbB3/
HER3 and ErbB4/HER4. HER2 displays tyrosine kinase
activity, but has no known ligand. ErbB family receptors
are activated by homodimerization or heterodimeriza-
tion. HER2 is activated either by ligand-independent
homodimerization when it is overexpressed, or by het-
erodimerization with a ligand-dependent ErbB/HER
member, in particular with ErbB3/HER3 [6].
Following the discovery of ERBB2 gene amplifications
in breast cancer, the HER2 receptor became an attractive
target for monoclonal antibody-based therapies. Trastu-
zumab is the first clinically approved humanized mono-
clonal antibody targeting HER2. It produced 11-26%
overall response rates as monotherapy for metastatic
breast cancer. In addition, as adjuvant to chemotherapy,
Trastuzumab significantly increased disease-free and
overall survival in both early stage and metastatic breast
cancers. Trastuzumab is effective only in HER2-ampli-
fied/overexpressing tumors and primary resistance to
therapy is a challenge [7]. Moreover, the majority of
metastatic breast cancer patients who initially respond
to Trastuzumab begin to demonstrate disease progres-
sion again within 1 year [8]. Trastuzumab resistance was
linked to many factors, including the overexpression of
other ErbB/HER family receptors and/or their ligands
[9,10], insulin-like growth factor receptors [11,12],
MUC4 [13] and soluble extracellular domain (ECD) of
HER2 circulating in the blood [14,15], activating PI3K
mutations [16], PTEN deletions [17], downregulation of
cyclin-dependent kinase inhibitor p27 [18] and increased
Akt activity [19,20].
HER2-HER3 heterodimer is known to be the most po-
tent activated form of HER2 in terms of strength of
interaction, ligand-induced tyrosine phosphorylation and
down-stream signaling. Indeed, HER3 might be a neces-
sary partner for HER2-mediated oncogenic activity in
HER2-overexpressing tumors [6]. The ECD of HER2 is
composed of four subdomains and Trastuzumab is
directed to its subdomain IV [21]. The antibody inhibits
HER2 activation [6], but cannot prevent HER2-HER3heterodimerization [22]. Pertuzumab is another antibody
directed to another epitope that is located at subdomain
II, which is involved in receptor dimerization [23]. It
appears to be more effective than Trastuzumab, in par-
ticular in low HER2-expressing tumor cells because of
its ability to interfere with HER2-HER3 heterodimeriza-
tion [23]. Pertuzumab and Trastuzumab were shown to
act synergistically against breast cancer cell survival [24],
suggesting that antibodies against different epitopes of
the ECD are able to generate not only additive but also
synergistic cellular responses. The limited efficacy of
Trastuzumab for cancer therapy, problems of acquired
resistance and the potential impact of novel anti-HER2
antibodies as therapeutic partners or alternative thera-
peutics justify more investment on HER2 targeting with
novel monoclonal antibodies. Here, we describe five
novel monoclonal antibodies directed against an epitope
(or epitopes) restricted to the native conformation of
HER2 ECD. In vitro studies provide evidence for anti-
cancer activity of these antibodies. More interestingly,
these novel antibodies appear to interact with tumor ne-
crosis factor-α (TNF-α) in a cell-dependent manner,
generating both synergistic and antagonistic growth
responses.
Methods
Reagents
A disulfide-linked homodimer of histidine-tagged extra-
cellular domain of HER2 fused to human IgG1 Fc do-
main (HER2 ECD), a similar construct based on EGFR
extracellular domain (EGFR ECD), and IgG1 isotype
control antibody were from R&D Systems (MN, USA).
Alkaline phosphatase (AP)- and horseradish peroxidase
(HRP)-conjugated secondary antibodies to mouse and
human IgGs, propidium iodide, trichloroacetic acid
(TCA), Sulforhodamine B (SRB), Incomplete Freund’s
Adjuvant, anti-calnexin antibody (#C4731), p-nitrophe-
nyl phosphate, disodium salt (PNPP), 4', 6-diamidino-2-
phenylindole (DAPI), insulin and Bromodeoxyuridine
(BrdU) were from Sigma Aldrich (MO, USA). Anti-
HER2 CB11antibody (#ab8054) was from Abcam (MA,
USA). Anti-BrdU antibody (#M0744) was from Dako
(Glostrup, Denmark). Anti-Akt (#9272), anti-phospho-
Akt (#9271), anti-Erk 1/2 (#9107), anti-phospho-Erk 1/2
(#9106) antibodies were from Cell Signaling (MA, USA).
Anti-phospho-HER2 (#sc-1011694) and anti-Cyclin D1
(#sc-246) antibodies were from Santa Cruz (California,
USA). Alexa Fluor 488-conjugated secondary antibodies
to mouse and human IgGs and Lipofectamine 2000 were
from Invitrogen (CA, USA). HiTrap Protein G HP col-
umns and ECL plus western blot detection kit were from
GE-Healthcare (WI, USA). Recombinant human TNF-α
was from PeproTech (NJ, USA). RNAse A and all re-
striction enzymes were from Fermentas (Vilnius,
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ase inhibitor cocktail tablets and phosSTOP (phosphat-
ase inhibitor cocktail) tablets were from Roche Ltd
(Basel, Switzerland). Antibody isotyping kit was from
Thermo Fisher Scientific Inc (IL, USA). Protein G
coupled Sepharose gel slurry was from East Coast Biolo-
gics (ME, USA).
Cell culture
SK-BR-3, MDA-MB-361, T47D, MCF-7 and BT-474 cell
lines were obtained from ATCC. Huh-7 cell line is used
in lab since 1995 and was last tested for authenticity in
2010 (originally from Jack Wands Lab at Massachusetts
General Hospital, Boston, MA). All breast cancer cell
lines have been tested and authenticated by short tan-
dem repeat profiling in September 2009 and February
2012, as described previously [25]. SK-BR-3 cells were
grown in McCoy’s 5A medium. MDA-MB-361, T47D,
MCF-7, BT-474 and Huh-7 cells were grown in Dulbec-
co’s Modified Eagle Medium (DMEM), as described
[25,26]. Hybridomas were grown in RPMI 1640, DMEM
or Serum Free Media (SFM) from Hyclone (IL, USA).
Cell culture media were purchased from GIBCO (CA,
USA), Sigma or Hyclone, and were supplemented with
10% fetal calf serum (FCS), 1% penicillin/streptomycin
(P/S), 1% non-essential amino acids and 1% L-glutamine,
unless otherwise stated. BT-474 cell growth medium was
supplemented additionally with 10 μg/ml insulin.
Fluorescent in situ hybridization analysis of ERBB2 copy
numbers
MCF-7, T47D, MDA-MB-361, SK-BR-3 and BT-474 cells
were harvested at confluence and fixed in Carnoy’s fixative
(3:1 methanol/glacial acetic acid). A dual-color FISH was
performed with Texas Red-labeled ERBB2 and FITC-
labeled chromosome 17 α-satellite (D17Z1) DNA probes
mix (LPS 001; Cytocell Ltd, Cambridge, UK), as described
by supplier with minor modifications. The slides were
treated at 72°C for 2 min in denaturation solution contain-
ing 70% formamide, 2XSSC (3 M NaCl, 0.3 M sodium cit-
rate, pH 7.0). The probe mixture was applied onto slides;
the area was covered with a 22X22 mm glass coverslip,
sealed with rubber cement. Slides were placed on a hot
plate and heated at 75°C for 5 min. The hybridization was
done overnight at 37°C in humidified chambers. Post-
hybridization washes were done once with 0.4XSSC at 72°C
for 2 min and once with 2XSSC containing 0.05%
Tween 20, at room temperature for 30 s. After post-
hybridization washes, the slides were dehydrated in a
series of 70%, 85%, and 97% ethanol. Air-dried slides were
counterstained with 4,6-diamidino-2-phenylindole (DAPI)
in an anti-fade solution. Copy numbers in >100 nuclei of
each cell line were counted under a Nikon Eclipse E600
epifluorescence microscope (Nikon Corp., Tokyo, Japan)equipped with filter sets appropriate for DAPI, FITC, and
rhodamine. Individual single-color images of DAPI, FITC,
and rhodamine were acquired through a high-sensitivity
monochrome charge-coupled device (CCD) camera inte-
grated to a Power Macintosh. Digitally acquired individual
images were overlaid and operated with MacProbe image
analysis software (PCI Scientific Systems League City, TX,
USA). ERBB2 copy numbers and ploidy level based on
average counts of centromere 17 in interphase and meta-
phase FISH were evaluated according to international
standard cytogenetic nomenclature [27].
Generation of anti-HER2 monoclonal antibodies
Animal experiments described here have been pre-
approved by the Bilkent University Animal Experiments
Ethical Review Panel, and conducted at Bilkent Animal
House, which is certified by the Ministry of Agriculture of
Turkey. All procedures complied with the guidelines of
the Ministry of Agriculture (Official Gazette. No. 25464).
BALB/c mice were immunized five times with live SK-BR-
3 cells (5–10 × 106 cells in PBS) by intra-peritoneal injec-
tion at three-week intervals. As a final booster, each
mouse received 20 μg recombinant HER2 ECD protein
injected with incomplete Freund’s adjuvant. On the third
day of last immunization, mice were sacrificed and their
splenocytes were fused with SP2/O myeloma cells to pro-
duce hybridomas as previously described [28].
HER2 ECD ELISA assay
96-well Polysorb (NUNC, Roskilde, Denmark) microtiter
plates were coated overnight at 4°C with HER2-ECD
(25–50 ng/well) in carbonate buffer. Following satur-
ation with 1% BSA for one hour, plates were incubated
with hybridoma supernatants or purified primary anti-
bodies for 2–4 h, and bound antibodies were detected by
further incubation with AP-conjugated anti-mouse IgG
antibodies. Trastuzumab binding was tested using AP-
conjugated anti-human IgG antibodies. Phosphatase activity
was measured using PNPP substrate with absorbance (OD)
reading at 405 nm using μQuant ELISA reader (BioTek,
VT USA). The cross-reactivity tests with EGFR ECD were
performed under the same conditions, except that ELISA
plates were coated with EGFR ECD.
Antibody isotyping and affinity purification
The isotypes of monoclonal antibodies were determined
using a commercial kit. Selected hybridoma clones were
expanded and the antibodies were purified from the cul-
ture supernatants by FPLC using HiTrap Protein G HP
columns (GE Healthcare, WI, USA).
Immunofluorescence
Cells were seeded on coverslips in 6-well plates. After 36 h
of cell culture, they were fixed with 2% paraformaldehyde
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uration with 10% FCS, the fixed cells were incubated with
anti-HER2 antibodies for 90 min. Primary antibody bind-
ing was detected using Alexa Fluor 488 conjugated goat
anti-mouse IgG or Alexa Fluor 488 conjugated goat anti-
human IgG antibodies, depending on the type of the pri-
mary antibody. Nuclei were counterstained with DAPI
and cells were observed using Zeiss Axio Imager.A1
microscope (Jena, Germany).
Flow Cytometry
Cells (3-5×105) were fixed with 2% paraformaldehyde
and incubated 1 h with 5 μg/ml anti-HER2 antibodies or
IgG1 isotype control antibody (in 1% BSA and 0.5 mg/
ml NaN3 in PBS). Cells were then incubated 1 h with
Alexa-488-conjugated anti-mouse IgG antibody and the
percentage of positively stained cells were counted on
FACSCalibur (BD Biosciences).
Immunoprecipitation
For detection of endogenous HER2 protein, cells were
lysed in RIPA buffer (150 mM NaCl, 50 mM Tris–HCl
pH; 7.4, 1 mM EDTA, 1% Triton X-100, 1% Na-deoxy-
cholate, 0.1% SDS, 1X Protease Inhibitors) [29,30], 2 mg
protein were diluted with milder NP40 buffer (150 mM
NaCl, 50 mM Tris–HCl pH: 8, 1% NP40, 1X Protease
Inhibitors) and incubated with 20 μg antibody for 2 h on
a rotator at 4°C. Then, 200 μl Protein G-coupled Sephar-
ose gel slurry was added, and the mixture was incubated
4 h at 4°C.
Western blot
Following immunoprecipitation experiments, antigen-
antibody bound Protein G beads were boiled in
SDS-loading buffer; solubilized proteins were run on
8% or 4-12% gradient SDS-PAGE. Proteins subjected to
SDS-PAGE were transferred to PVDF membrane using
XCell II Blot Module (Invitrogen, CA, USA). Unoccupied
protein binding sites on the PVDF membrane were satu-
rated by incubating with 5% dried milk (in TBS-T) for 1 h.
Full length and truncated forms of HER2 protein were
detected using CB11 antibody directed against intracellu-
lar domain. Briefly, membranes were incubated overnight
with CB11 antibody (1/500 dilution), followed by 1 h incu-
bation with HRP-conjugated secondary antibodies to
mouse IgGs and bound antibody was detected using ECL
plus western blot detection kit.
Epitope mapping
The experiment was based on testing of antibody bind-
ing to HER2 proteins that have been modified by dele-
tion of different subdomains of its ECD. Mammalian
expression plasmids were constructed and transiently
transfected into Huh-7 cells. Antibody binding wastested by combined immunoprecipitation-western blot
and indirect immunofluorescence assays. A pDEST26-
derived plasmid vector expressing full-length human
HER2 protein (OCABo5050G0219D; shortly called
p219D here) was obtained from Source BioScience Life-
Sciences (Nottingham, UK). HER2 extracellular domain
was extracted from p219D by Sac I/Eco RI digestion
leaving the coding sequence for the N-terminal 22
amino acid signal peptide intact. pCC2001 was produced
by inserting Not I and Xho I sites between this sequence
and the sequence encoding the rest of HER2 protein
starting from the transmembrane domain. DNA
sequences allowing the inclusion of domains I, II, III and
IV of ECD under different combinations were amplified
by PCR and inserted into pCC2001 plasmid using the
Not I and Xho I sites. The integrity of cloned sequences
has been verified by DNA sequencing. Huh-7 cells
(6×105) were transfected in 6-well plates with different
HER2 plasmid constructs (5 μg each) using Lipofecta-
mine 2000, following a protocol provided by the manu-
facturer. Following 8-h Lipofectamine incubation, cells
were washed with PBS and incubated overnight with
fresh complete media (without P/S). Next day, the cells
were trypsinized and replated. On the second day of
cell-expansion, the cells were collected, lysed in RIPA
buffer and subjected to immunoprecipitation and west-
ern blot analyses as described above, except that 150 μg
proteins were immunoprecipitated using 15 μg antibody.
Cell growth assay
This assay was performed as described previously [31].
Briefly, cells (103) were seeded in 96-well plates in tripli-
cate and allowed to attach by 2 h of preincubation. Anti-
bodies were diluted in cell culture medium and added to
preincubated cells to obtain 0–20 μg/ml concentrations
under a final volume of 200 μl medium/well. Cells were
then incubated up to 6 days. TNF-α treatment was per-
formed similarly except that cells were preincubated for
6 h. For antibody and TNF-α co-treatment experiments
and checkerboard assays, cells were preincubated for 2 h
for attachment, followed by 4-h incubation with anti-
bodies prior to TNF-α addition. At the end of each time
point, culture supernatants were discarded. Attached
cells were washed twice with PBS, fixed with ice-cold 10%
TCA for one hour, followed by Sulforhodamine B-based
reading, as described [32].
Drug interaction modeling
Drug interaction scores for pairwise combinations of
TNF-α with individual antibodies at fixed concentrations
were calculated as follows. Growth level in a drug condi-
tion was defined as the growth measurement in the drug
condition normalized by growth measurement under no
drug. To understand the interaction between an
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levels under single antibody, TNF-α, antibody + TNF-α
were compared. Expected growth level under no drug
interaction was defined for each pairwise drug combin-
ation as the multiplication of the growth levels under
each individual drug, following the Bliss Independence
Model for drug interactions [33]. The observed growth
level for each combination was divided by the expected
growth level to find an interaction score. According to
this analysis, a score of 1 means no interaction, or inde-
pendence, a score smaller than 1 means synergy, and a
score larger than 1 means antagonism. For the drug
interaction experiments where more than one concen-
tration combination was experimentally tested, a single
interaction score between two drugs was computed. For
this, a modified version of the above algorithm and the
data from all concentration combinations was used, as
described previously [34]. The scores and the scale of
these scores are equivalent to the single combination
drug interaction experiment and are interpreted in the
same way (<1 = synergy; >1 = antagonism). Each inter-
action experiment was done in triplicate, and the average
growth levels were used for interaction score calculation.
Bromodeoxyuridine incorporation assay
Cells (104) were plated on coverslips in 12-well plates, and
treated as described for cell growth assays. At 48th hour,
BrdU (10 μg/ml) was added into cell culture media and
cells were further incubated for 24 h. The detection of
BrdU incorporation was performed as described previously
[35], except that Alexa Fluor 488-conjugated anti-mouse
IgG antibody was used for visualization. Cell nuclei were
counterstained with DAPI, examined using Zeiss Axio
Imager.A1 microscope and representative photographs
(3–5 frames per coverslip) were acquired. Percent BrdU
incorporation was calculated after manual counting of
BrdU-positive (BrdU+) and BrdU-negative (BrdU-) nuclei.
Cell cycle analysis
Analyses were performed as described previously [36].
Briefly, 2.5×104 (for 6-day samples) or 105 (for 1 and 3-
day samples) SK-BR-3 cells were seeded in 6-well dishes
in McCoy’s 5A medium. After 36 h incubation, the
medium was replaced with fresh McCoy’s 5A medium
including BH1 or IgG1 isotype control antibody (final
5 μg/ml) ± 1000Unit/ml TNF-α. On days 1, 3 and 6 after
the addition of antibodies, both suspended and adherent
cells were collected, fixed and stained with propidium
iodide (PI). PI-stained cells were measured and analysed
by flow cytometry.
Analysis of the downstream protein expression
In order to analyze the effect of BH1 treatment on the
downstream pathway, SK-BR-3 cells were treated for 1–24 h with 10 μg/ml BH1, 1000 Unit/ml TNF-α alone or
their combination. Cells collected at each time point
(1st, 2nd, 4th, 8th, 12th, 24th hour) were lysed with RIPA
buffer (containing 1X PhosSTOP). Solubilized proteins
were resolved by SDS-PAGE and analyzed by immuno-
blotting. PVDF membranes initially used for detection of
phospho-Akt, phospho-Erk 1/2 and phospho-HER2 pro-
teins were stripped once (62.5 mM Tris-Cl pH: 6.7, 2%
SDS, 100 mM β-mercaptoethanol), washed thoroughly
with TBS-T and re-blotted with anti-Akt, anti-Erk 1/2,
anti-cyclin D1 and anti-calnexin antibodies. Following
incubation with HRP-conjugated secondary antibodies
to mouse or rabbit IgGs, bound antibodies were detected
using ECL plus western blot detection kit.
Statistical analysis
Experimental data were presented as mean ± SD. Statis-
tical analysis of experiments that have been performed
at least in triplicate was done using Student’s t test.
Results
Novel monoclonal antibodies directed to extracellular
domain of HER2
We used a combined immunization protocol with
repeated injections of live SK-BR-3 cells to BALB/c mice,
followed by a single injection of recombinant HER2
ECD protein. Hybridoma clones were screened by HER2
ECD ELISA assay. Five hybridoma clones (namely BH1,
BH2, BH5, BH6 and BH7) were selected for further ana-
lyses, based on their reactivity with HER2 ECD, but not
EGFR ECD (Additional file 1). All monoclonal anti-
bodies were isotyped as IgG1 with κ-light chains. Anti-
bodies were purified from hybridoma supernatants using
Protein G affinity chromatography and used for further
studies.
Antibody reactivities against breast cancer cell lines
Anti-HER2 antibodies were tested using five breast can-
cer cell lines with different ERBB2 copy numbers. Fluor-
escence in situ hybridization (FISH) using probes against
ERBB2 gene and chromosome 17 centromere showed
that MCF-7 had three chromosome 17 and two ERBB2
signals. MDA-MB-361 provided 4–8 chromosome 17,
and 8–12 ERBB2 signals. Both SK-BR-3 and BT-474 dis-
played 5–6 chromosome 17 signals and highly amplified
ERBB2 signals (Figure 1, left panel). Most of T47D cells
displayed three chromosome 17 and three ERBB2 copies
(data not shown). These findings were in perfect agree-
ment with a previous study reporting 47, 43, 11 and 2.5
copies of the ERBB2 gene in BT-474, SK-BR-3, MDA-
MB-361 and MCF-7, respectively [37]. When tested by
indirect immunfluorescence assay, all five anti-HER2
antibodies displayed strong fluorescence intensities with
both BT-474 and SK-BR-3 cells. The signals obtained
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Figure 1 Strong binding of anti-HER2 antibodies to ERBB2-amplified breast cancer cell lines. ERRB2 amplification was analyzed by FISH
analysis. Cells were harvested at confluence, fixed and subjected to dual-color FISH using Texas Red-labeled ERBB2 (red) and FITC-labeled
chromosome 17 α-satellite CEP17 (green) DNA probes (left panel). For generation of anti-HER2 monoclonal antibodies, mice were immunized
with SK-BR-3 cells, followed by a recombinant protein composed of extracellular domain of HER2 fused to human IgG1 Fc domain (HER2 ECD).
Antibodies were purified from conditioned hybridoma cell culture media by affinity chromatography. For immunofluorescence assay, cells were
seeded on coverslips in 6-well plates, incubated 36 h in cell culture medium, fixed, and permeabilized. Fixed cells were incubated with anti-HER2
antibodies, and the primary antibody binding was detected using Alexa 488- conjugated anti-mouse IgG (BH1, BH2, BH5, BH6, BH7 panels; green).
Nuclei were counterstained with DAPI (blue) and pictures were acquired using Zeiss Axio Imager.A1 microscope.
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those provided by MCF-7 were negative or barely detect-
able (Figure 1, BH1, BH2, BH5, BH6, BH7 panels).
The binding strengths of antibodies were compared
using HER2 ECD ELISA and flow cytometry. ELISA test
provided evidence of strong binding capacity for BH1,
BH6 and BH7 antibodies. BH5 antibody displayed lowest
binding capacity, whereas BH2 had intermediate activity.
These observations strongly suggested that we produced
three anti-HER2 antibodies with high affinity, one with
low and one with intermediate affinities (Figure 2A).
Flow cytometric analyses provided similar findings.
When tested with T47D breast cancer cell line expres-
sing low levels of HER2 [38], BH1 and BH6 displayed
highest shifts in staining intensity as compared to iso-
type control antibody. The binding of BH5 was not de-
tectable, whereas BH2 displayed a weak binding
(Figure 2B). However, when tested with BT-474 that has
ERBB2 gene amplification (Figure 1, left panel), all anti-
bodies displayed strong intensity shifts, BH1 producing
the best shift (Figure 2C).Newly generated anti-HER2 antibodies recognize
conformation-dependent epitopes
Bioactive antibodies that are most effective against HER2-
overexpressing tumors recognize conformational epitopes
located at ECD subdomains involved in either receptor ac-
tivation [21] or receptor dimerization [23]. Thus, the bio-
activity of anti-HER2 antibodies may be strongly
dependent on how they occupy the critical regions on
their target. We performed a series of analyses to identify
epitopes recognized by newly raised monoclonal anti-
bodies. In these studies, Mouse IgG1 isotype antibody and
humanized Trastuzumab were used as negative and posi-
tive controls, respectively. NCL-CB11 (CB11 in short)
antibody against intracellular domain of HER2 was also
used. Initially performed western blot assays using differ-
ent breast cancer cell line lysates provided positive signals
with CB11 antibody, but not with others (data not shown).
Based on these findings, we hypothesized that the epitope
(s) recognized by our antibodies were unstable under de-
naturing conditions of SDS-PAGE, although they
remained stable after paraformaldehyde fixation used in
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Figure 2 Binding affinities of anti-HER2 antibodies. (A) HER2 ECD ELISA assay showing the binding strengths of five monoclonal antibodies.
HER2 ECD-coated plates were incubated with increasing concentrations of anti-HER2 antibodies, followed by alkaline phosphatase-conjugated
anti-mouse IgG antibodies. Y axis shows the absorbance (OD) reading at 405 nm following incubation with alkaline phosphatase substrate. T-bars:
SD. (B) and (C), Flow cytometric analysis of antibody binding to low HER2-expressing T47D (B) and high HER2-expressing BT-474 (C) breast cancer
cells. Fixed single-cell suspensions were incubated with anti-HER2 antibodies, followed by Alexa-488-conjugated secondary antibodies and
fluorescence intensities were measured using flow cytometry.
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ments (Figures 1, 2). Next, we tested whether our anti-
bodies were able to immunoprecipitate HER2 from cell
lysates made in RIPA buffer. Cell lysates made from T47D
cells were subjected to immunoprecipitation with our
antibodies and antibody-bound proteins were tested by
western blot assay using CB11 antibody. All antibodies
tested were able to immunoprecipitate HER2 under these
conditions. The signal obtained with BH5 antibody wasweak, as expected (Additional file 2). These findings pro-
vided evidence that newly generated antibodies recognized
conformation-dependent epitope(s) on endogenously
expressed HER2 protein.
Discovery of a new epitope(s) restricted to the intact
form of the extracellular domain of HER2
In order to delineate the epitope(s) recognized by the anti-
bodies, we constructed a series of plasmids to express
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cells that express low levels of endogenous HER2 protein
[39] were transiently transfected with plasmids to express
different forms of HER2, and immunoreactivity of each
antibody was tested by indirect immunofluorescence and
western blotting following immunoprecipitation. In im-
munofluorescence assay, CB11 antibody that was used as
a positive control for expression of full length and trun-
cated forms of HER2 transgene identified strongly positive
transfected cells with all plasmids tested (Figure 4, right
panel). Another control was Trastuzumab that is directed
against an epitope located at domain IV of the extracellu-
lar region of HER2 [21]. All truncated forms of HER2 pro-
tein containing domain IV provided strongly positive
signals with Trastuzumab (Figure 4, Tzm panel). Surpris-
ingly, all five of our antibodies recognized only full-length
HER2. They did not react with recombinant HER2 protein
forms lacking any one of the ECD subdomains (Figure 4,
panels BH1, BH2, BH5, BH6, BH7). Immunoprecipitation-
western blotting assays following transient expression of
full length and four truncated forms of HER2 confirmed
immunofluorescence findings (Additional file 3). We
deduced that newly generated antibodies are directed to
an epitope, or closely related epitopes present only on
structurally intact ECD of HER2. In other words, the re-
activity of antibodies was lost when any of the four subdo-
mains of the HER2 ECD was deleted. Thus, all five
antibodies described in the report required the structural
integrity of ECD for recognition of HER2 receptor
(Figure 3).I II III IV
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Figure 3 Schematic representation of antibody epitope mapping stud
(p219D) or partially deleted HER2 were transfected into Huh7 cells. Anti-HE
(Figure 4) and immunoprecipitation-western blotting (Additional file 3) tech
ECD. Grey box: transmembrane domain, TK: tyrosine kinase domain, CT: car
antibody reactivity. Stars (*) near plasmid names indicate that immunofluor
assay.Effect of anti-HER2 antibodies on cell growth
The bioactivity of antibodies was first tested against SK-
BR-3 cells. Affinity purified anti-HER2 antibodies were
added at increasing concentrations into the culture
media and relative cell growth was tested following
6 days of cell culture. Only BH6 and BH1 antibodies dis-
played modest but significant inhibitory effect on target
cells, by lowering relative cell growth to 65% and 73%
respectively, as compared to isotype control antibody
(Figure 5A; p < 0. 006 at 10 μg/ml antibody concentra-
tion). In contrast, BH2, BH5 and BH7 antibodies did not
affect the growth of SK-BR-3 cells.
Effects of anti-HER2 antibodies in combination with
tumor necrosis factor-α
It has been previously reported that amplified expression
of HER2 in breast cancer cells induces resistance to
TNF-α cytotoxicity [40,41] that can be sensitized by
Trastuzumab [42]. Therefore, we asked whether our
anti-HER2 antibodies were able to sensitize SK-BR-3
cells to TNF-α. We performed antibody treatment
experiments in the presence of 1000 U/ml of TNF-α
(Figure 5B). In the absence of antibody, TNF-α alone
induced nearly 50% growth inhibition. This effect was
not modified significantly in the presence of increasing
concentrations of IgG1 isotype control antibody (up to
10 μg/ml tested). In sharp contrast, all five anti-HER2
antibodies strongly enhanced TNF-α-induced growth in-
hibition (p < 0.0005 at 10 μg/ml antibody concentration).
As little as 0.25 μg/ml anti-HER2 antibody was sufficient1 BH2
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Figure 4 Epitope mapping of anti-HER2 antibodies using indirect immunofluorescence assay. Huh7 cells were transfected in 6-well plates
using a set of mammalian expression plasmids encoding full-length or N-terminally truncated HER2 protein. Transfected cells were cultivated for
48 h, and subjected to indirect immunofluorescence assay. Transfected cells that were recognized by specific antibodies displayed strong green
fluorescence. The letters from (a) to (k) indicate the plasmids in the following order: pDEST26 (empty vector), p219D, pCC2001, pCC2005,
pCC2004, pCC2003, pCC2002, pCC2008, pCC2007, pCC2006, pCC2012 (see Figure 3 for description of HER2-expression plasmids). (−) No primary
antibody, Tzm: Trastuzumab, CB11: a monoclonal antibody recognizing an epitope at intracellular domain of HER2 that was used as a positive
control for expression of transfected plasmids.
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http://www.biomedcentral.com/1471-2407/12/450to significantly enhance TNF-α-mediated growth inhib-
ition, as compared to IgG1 isotype control antibody at
the same concentration (p < 0.005). Only one antibody,
namely BH7, displayed a slightly weaker enhancer activ-
ity, reaching significance at 1.25 μg/ml concentration
(p <0.02). Enhancer effects of anti-HER2 antibodies
were nearly saturated at 2.5 μg/ml concentration,
reaching to 80-90% growth inhibition depending on
antibody (Figure 5B).
Cell-dependent interactions between anti-HER2
antibodies and tumor necrosis factor-α creating both
synergistic and antagonistic growth effects
Based on observations with SK-BR-3 cells, we analyzed
interactions between anti-HER2 antibodies and TNF-α,using five different breast cancer cell lines. We com-
pared growth responses to (i) 5 μg/ml of each individual
antibody, (ii) 1000 U/ml of TNF-α, and (iii) 5 μg/ml
antibody and 1000 U/ml of TNF-α in combination. An
interaction score for each combination was calculated as
described in the Methods, where a score of 1 means no
interaction, or independence; a score smaller than 1
means synergy, and a score larger than 1 means antag-
onism [32]. In Figure 6, we analyzed TNF-α and anti-
HER2 antibody interactions as compared to IgG1 isotype
control antibody. IgG1 control antibody interactions
with TNF-α provided scores between 0.81-0.88. There-
fore, we considered values between 0.8-1.2 as an indica-
tion of non-interaction. When tested with SK-BR-3 cell
line, interaction scores obtained for TNF-α and new
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Figure 5 Anti-HER2 antibodies exhibit enhanced anti-growth
effect in the presence of tumor necrosis factor-α in SK-BR-3
cells. (A) SK-BR-3 cells were plated onto 96-well plates and
incubated at 37°C with 5% CO2. After 2 h of incubation, antibodies
(0–10 μg/ml) were added, and cells were incubated for 6 days. (B)
Antibodies (0–10 μg/ml) were added as described in (A), and cells
were incubated for 4 h prior to TNF-α (1000 U/ml) addition to the
culture medium. Cells amount was determined by Sulforhodamine B
assay after 6 days of treatment. T. Bars, SD; * p < 0.006, ** p < 0.0005,
(A, B).
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Figure 6 Synergy and antagonism between anti-HER2
antibodies and tumor necrosis factor-α. Anti-Her2 antibodies and
TNF-α acted synergistically in SK-BR-3 cells (top), but antagonistically
in BT-474 cells (bottom). Growth effects observed under antibody
(white columns), TNF-α (striped columns), and antibody + 1000 TNF-
α (black columns) were obtained as follows. Cells were plated onto
96-well plates and incubated at 37°C with 5% CO2. After 2 h of pre-
incubation, antibodies (5 μg/ml) were added, and cells were
incubated for 6 days to study the effects of antibodies alone (white
columns). The effects TNF-α (1000 U/ml) alone (striped columns)
were studied by adding this cytokine into cell culture medium after
4 h of pre-incubation. For combined treatments, antibodies (5 μg/
ml) and TNF-α (1000 U/ml) were added after 2 h and 4 h of pre-
incubations, respectively (black columns). Cells amount was
determined by Sulforhodamine B assay after 6 days of treatment.
Growth level under a drug condition was defined as the growth
under that condition normalized by growth under no drug
condition. Expected growth level under no interaction (gray
columns) was calculated by multiplying the growth levels under
each individual drug. The observed growth level for each
combination was divided by the expected growth level to find an
interaction score according to Bliss Independence Model for drug
interactions (displayed under each antibody label). The combination
of TNF-α with isotype control antibody (IgG1) or Trastuzumab (Tzm)
provided scores near 1, meaning no interaction or independence in
both cell lines. New anti-HER2 antibodies provided scores less than
0.57 in SK-BR-3 cells, meaning synergy. In contrast their interaction
scores were more than 1.40 in BT-474 cells, meaning antagonism.
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http://www.biomedcentral.com/1471-2407/12/450anti-HER2 antibody combinations ranged between 0.26
and 0.48 (Figure 6, top). Synergy scores obtained with
BH1, BH2 and BH5 were particularly strong (scores:
0.35, 0.30 and 0.26, respectively). In contrast, there was
no interaction between Trastuzumab and TNF-α
(score = 0.95). Thus, all five new anti-HER2 antibodies
acted synergistically with TNF-α to inhibit the growth of
SK-BR-3 cells.
Further studies indicated that the interaction between
anti-HER2 antibodies and TNF-α was cell-dependent.
Indeed, we observed a completely opposite response
with another breast cancer cell line, namely BT-474
(Figure 6, bottom). This cell line responded to a few
anti-HER2 antibodies modestly albeit significantly (BH1,
p < 0.05; Tzm, p < 0.003). The response to TNF-α alone
was about 50% growth inhibition, as observed with
SK-BR-3 cells. Novel anti-HER2 antibodies abolished
TNF-α-induced growth inhibition either completely (BH1,BH2, BH5, BH7) or partially (BH6) in BT-474 cells. Inter-
actions scores of novel anti-HER2 antibodies ranged be-
tween 1.40 and 3.08, all indicative of an antagonistic
interaction with TNF-α. Again, Trastuzumab had no
major interaction with TNF-α (score = 1.21). Data on
B
H
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1.07
MDA-MB-361
1.19
SK-BR-3
0.86
0.54
0.405
0.27
0.135
Growth
Measurement
(OD)
B
H
1
B
H
1
B
H
1
Figure 7 Anti-HER2 antibody and tumor necrosis factor-α
interaction is cell type-specific. The growth of breast cancer cell
lines under various combinations of BH1 antibody (0, 0.161, 0.312,
0.625, 1.25, 2.5, 5.0 μg/ml) and TNF-α (0, 8, 16, 32, 62.5, 125, 250, 500
U/ml) treatments was experimentally tested in triplicate and the
average relative growth levels were calculated. Heatmap represents
the cell growth (as measured by OD) under different conditions.
Synergistic and antagonistic interactions are indicated by green and
blue dots, respectively. Numbers associated with cell line names
indicate interaction scores. According to this checkerboard assay,
BH1 and TNF-α show synergy in SK-BR-3 cells, but antagonism in BT-
474 and MDA-MB-361 cells. There is no interaction in MCF-7 cells.
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http://www.biomedcentral.com/1471-2407/12/450interaction analyses performed with MDA-MB-361, MCF-
7 and T47D were shown in Additional file 4. When tested
alone with MDA-MB-361 cells, some antibodies (BH1,
BH2, BH7) displayed significant growth inhibition (>50%
inhibition, p < 0.0003). Trastuzumab had no detectable
anti-growth effect, but BH5 and BH6 displayed only mod-
est activity (27% and 35% growth inhibition, respectively;
p < 0.02). TNF-α was highly toxic to this cell line causing
>95% growth inhibition. Antibody co-treatments rescued
TNF-α induced growth inhibition only slightly. Thus, drug
interaction analysis was not conclusive. The growth of
MCF-7 cells did not appear to be affected by antibody
treatment. In contrast, these cells were the most sensitive
ones to TNF-α with nearly 100% growth inhibition.
Antibody co-treatments did not change their response
to TNF-α. T47D cells were resistant to both anti-HER2
antibody and TNF-α treatments, either alone or in
combination.
Detailed analysis of interaction between BH1 antibody
and tumor necrosis factor-α
Drug interaction analyses described above were per-
formed using fixed amounts of antibodies and TNF-α.
We obtained clear-cut results with only SK-BR-3 and
BT-474 cells. Therefore, we decided to test the effects of
combined treatment of anti-HER2 antibody BH1 and
TNF-α on four breast cancer cell lines using a checker-
board assay. BH1 was selected as a representative of
newly generated anti-HER2 antibodies. Each cell line
was grown on a 7×8 grid of BH1 antibody and TNF-α
combinations. The concentration of TNF-α was
increased on the x-axis (0, 8, 16, 32, 62.5, 125, 250 and
500 U/ml) and the concentration of BH1 antibody was
increased on the y axis (0, 0.16, 0.312, 0.625, 1.25, 2.5
and 5 μg/ml). Such an experimental setting allowed us
to measure the growth of each cell type in 42 concentra-
tion combinations of BH1 antibody and TNF-α, in
addition to the growth of cells under each ‘drug’ alone.
This experiment was done in triplicate for each cell type.
The average growth measures are shown in Figure 7.
We analyzed the growth measures using the same defin-
ition of drug synergy based on Bliss Independence
Model as described above. We found concentration
combinations where BH1 and TNF-α are significantly
synergistic or antagonistic, which are indicated as green
or blue dots on Figure 7, respectively. For each of the
drug interaction experiments, we next computed a single
interaction score as described previously [34]. These
scores, which are interpreted as described above, are
shown in Figure 7. According to this, BH1 and TNF-α
exhibited synergy in SK-BR-3 cells, while they were an-
tagonistic in BT-474 and MDA-MB-361 cell types, when
all concentration combinations are considered. Interest-
ingly, BH1 antibody, even at a very low dose (0.16 μg/ml),strongly suppressed the growth inhibition triggered by
TNF-α in BT-474 cells. These observations confirm strong
synergistic and antagonistic interactions of TNF-α and
anti-HER2 antibodies in SK-BR-3 and BT-474, respectively
(Figure 6). The interaction score for MCF-7 was very close
to 1, suggesting independence.
Mechanisms of growth inhibition by anti-HER2 antibodies
and tumor necrosis factor-α
In cancer cells, overexpressed HER2 is believed to be
constitutively active as homodimers and/or as heterodi-
mers with ligand-dependent HER3 [6]. Downstream sig-
naling from HER2 involves PI3K-dependent activation of
Akt and Ras-dependent activation of ERK1/ERK2 pro-
teins by phosphorylation, mediating cell survival and
proliferation activities of HER2 [6]. Therapeutically rele-
vant Trastuzumab and Pertuzumab antibodies inhibit
both Akt and ERK1/ERK2 phosphorylation, leading to
growth inhibition [24,43-45]. TNF-α signaling generates
both cell survival and apoptosis signals, depending on
the activation of NFκB transcription factor [46]. We fur-
ther investigated the mechanisms of growth inhibition in
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http://www.biomedcentral.com/1471-2407/12/450responsive SK-BR-3 cells. As shown in Figure 8 left
panel, untreated SK-BR-3 cells displayed relatively stable
expression of phospho-HER2, phospho-Akt, total Akt,
phospho-Erk1/2 and total Erk1/2. Cyclin D1 levels were
undetectable under this experimental condition. Cells
treated with 10 μg/ml BH1 antibody inhibited Akt phos-
phorylation that was clearly detectable between 8 h and
24 h of treatment. There was also a partial inhibition of
Erk1/2 phosphorylation between 4 h and 24 h of treat-
ment. In parallel with these changes, we also observed
progressive accumulation of cyclin D1 levels detected as
early as 4 h of treatment. In contrast, HER2 phosphoryl-
ation was not affected by antibody treatment (Figure 8
middle panel). Cells co-treated with 10 μg/ml BH1 and
1000 U/ml TNF-α displayed essentially the same type of
alterations (Figure 8 right panel). Thus, TNF-α appeared
not to modify the effects of the anti-HER2 antibody on
phospho-Akt, phospho-ERK1/2 and Cyclin D1 in SK-
BR-3 cell line. Indeed, treatment of cells with 1000 U/ml
TNF-α alone did not affect any of the parameters stud-
ied, except a delayed inhibition of Akt phosphorylation
at 24 h (Additional file 5).
Cyclin D1 accumulates in G1 and G2 phases of cycling
cells with a loss of expression in S phase cells [47]. Ac-
cordingly, Cyclin D1 accumulation could indicate pro-
gressive accumulation of cells at G1 and G2/M phases
under anti-HER2 antibody treatment. We tested this hy-
pothesis by exposing BH1 and/or TNF-α-treated cells to
BrdU labeling and cell cycle analysis experiments during
6 days of treatment. Tests were performed at days 1, 3
and 6 (Figure 9A). SK-BR-3 cells have doubling times
varying between 15 h and 36 h [48,49]. In order to de-
tect the ratio of cells at G1/G0 phase, we used apAkt
Calnexin
Cyclin D1
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Erk1/2
Akt
pErk1/2
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Figure 8 In vitro molecular responses of SK-BR-3 cell to anti-HER2 ant
up to 24 h with BH1 antibody (10 μg/ml), TNF-α (1000 U/ml) or the combi
at indicated times (hr, hours) and the expressions of phospho-HER2 (pHER2
(pErk1/2), total Erk1/Erk2 (Erk 1/2) and Cyclin D1 were analyzed by western
incubated in a parallel experiment in the absence of any treatment.modified DNA labeling protocol by exposing cells to
BrdU for 24 h prior to each experimental time. As com-
pared to IgG1 isotype control antibody, BH1 induced a
significant decrease in the number of BrdU+ cells at days
3 and 6 (p ≤ 0.05). Treatment of cells with IgG1 and
TNF-α resulted in a more pronounced decrease of BrdU+
cells that dropped progressively to 35% at day 6. When
compared to IgG1 + TNF-α-treated cells, BH1 + TNF-
α-treated cells responded immediately by a radical de-
crease of BrdU incorporation rates to 25% and 26% at
days 1 and 3, respectively (p≤0.05). However, this inhib-
ition was not stable and reversed to 37% at day 6
(Figure 9A). These findings indicated that both BH1 and
TNF-α significantly increased the number of cells at G1/G0
phase, although this effect was delayed in BH1-only
treatment. Sharp and immediate decrease in BrdU (+)
cells with BH1 + TNF-α co-treatment confirmed the
synergy between BH1 and TNF-α in these cells. Cell
cycle analyses confirmed these findings (Figure 9B-D).
As compared to IgG1 isotype control antibody-treated
cells, BH1-treated cells first showed an increase in G2
cells at day 1, followed by a progressive increase of G1
cells at days 3 and 6. This was accompanied with a de-
crease in S phase cells. TNF-α treatment resulted in an
immediate and stable response with an increase in G1
cells, concomitant with a decrease of S phase cells at all
time points tested. BH1 + TNF-α treatment exaggerated
this response, leading to a stronger accumulation of G1
phase cells, associated with a depletion of G2 phase
cells. We concluded that both BH1 antibody and TNF-α
were able to induce sustained accumulation of SK-BR-3
cells at G1/G0 phase, and their combination amplified this
response particularly in early times of co-treatment.BH1
4 8 12 24
BH1 + TNF-α
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ibody BH1 and tumor necrosis factor-α. SK-BR-3 cells were treated
nation of both agents. Cell lysates were prepared from cells harvested
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Figure 9 Effects of anti-HER2 antibody BH1 and tumor necrosis factor-α on DNA synthesis and cell cycle in SK-BR-3 cells. (A) Effects on
DNA synthesis were tested by 24-h BrdU incorporation assay. Cells were plated on coverslips in 12-well plates, treated as described in Figure 5,
and were exposed to BrdU during 24 h prior to indicated days. Nuclear BrdU was detected by indirect immunofluorescence assay. Nuclei were
counterstained with DAPI, examined using Zeiss Axio Imager.A1 microscope. Representative photographs (3–5 frames per coverslip) were
acquired. Percent BrdU incorporation was calculated after manual counting of BrdU+ and BrdU- nuclei. * Denotes p-values≤ 0.05 (BH1 vs. IgG1,
BH1 + TNF-α vs.IgG1 + TNF-α). T-bars: SD. (B-D). Effects on cell cycle were analyzed by flow cytometry. SK-BR-3 cells were treated with 20 μg/ml
BH1 or IgG isotype control antibody in the presence or absence of 1000 U/ml TNF-α. Cells were fixed on day 1 (B), day 3 (C) and day 6 (D),
stained with propidium iodide and the cell cycle distribution was analysed with flow cytometry. Fraction of cells present in G2/M-phase (G2/M),
S-phase (S) and G1-phase (G1) are shown in purple, green and orange respectively. Fraction of apoptotic cells observed as a SubG1 peak is
shown in black.
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This report describes five novel anti-HER2 monoclonal
antibodies that have been produced by immunizing mice
with HER2-overexpressing whole cells, followed by a
boost with recombinant HER2 ECD homodimer protein.
Immunoprecipitation and western immunoblotting stud-
ies indicated that all five antibodies were directed against
conformation-dependent epitope(s) present on the en-
dogenous HER2 protein. Epitope mapping with recom-
binant HER2 protein forms that have been truncated at
ECD domain indicated that all five antibodies react only
with the native form of cellular HER2, being unable to
recognize truncated proteins lacking any of the four sub-
domains. Although we do not yet know whether our
antibodies recognize identical, overlapping or independ-
ent epitopes on the intact ECD domain, it is evident that
their epitope(s) is different from those recognized by
Trastuzumab and Pertuzumab. Trastuzumab, a thera-
peutic antibody already approved for clinical use, recog-
nizes an epitope restricted to subdomain IV, involved inreceptor activation [21]. Pertuzumab, a therapeutic anti-
body tested in different clinical trials, recognizes a dis-
tinct epitope located on subdomain II, involved in
receptor dimerization [23]. Antibodies directed to ECD
epitope(s) different from other anti-HER2 therapeutic
antibodies may serve as new analytical tools to study the
structural organization of HER2 at the cell surface that
may be present as monomers, homodimers and hetero-
dimers depending on cell type and extracellular environ-
ment such as the availability of ligands that activate
heterodimer partners of HER2. Dynamic changes at the
receptor ECD in relation with transcriptional, transla-
tional and post-translational modifications can be moni-
tored with these antibodies, both biochemically and
biologically.
In vitro effects of novel anti-HER2 antibodies were
tested against five different breast cancer cell lines display-
ing different degrees of ERBB2 amplification and HER2
expression. Individually tested novel anti-HER2 antibodies
were weakly effective as growth inhibitors (Figure 6). This
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http://www.biomedcentral.com/1471-2407/12/450was not surprising. Indeed, Trastuzumab (4D5) has a
modest growth inhibitory effect (56%), and Pertuzumab
(2C4), the best therapeutic alternative to Trastuzumab,
induces only 20% growth inhibition [42]. Based on the
synergy between Trastuzumab and Pertuzumab directed
to different epitopes of HER2 [24], we performed studies
to test combinatory anti-growth effects of our anti-HER2
antibodies with Trastuzumab on SK-BR-3 cells. Prelimin-
ary data suggested a synergy between them, raising the
possibility that our antibodies may be combined with
Trastuzumab or Pertuzumab to enhance anti-cancer activ-
ity. This will be the focus of further work.
The most striking feature of novel anti-HER2 antibodies
was their differential interaction with TNF-α depending
on cell type. They synergized with TNF-α on SK-BR-3 cells
by raising growth inhibition from 50% to nearly 90%. In
sharp contrast, the same antibodies displayed strong an-
tagonism with TNF-α on BT-474 cells and MDA-MB-361
cells by abolishing TNF-α-induced growth inhibition ei-
ther completely (BT-474 cells) or partially (MDA-MB-361
cells). Trastuzumab did not have any synergistic or antag-
onistic effects on TNF-α-mediated growth inhibition in
these cell lines (Figure 6). The sensitization of SK-BR-3
cells to TNF-α cytotoxicity by mouse monoclonal anti-
body 4D5 (from which Trastuzumab has been humanized)
has been reported [42], but there is no previous data on
synergy or antagonism between anti-HER2 antibodies and
TNF-α, to our best knowledge.
TNF-α is one of the most potent anti-tumor factors
when used at high concentrations, but its systematic tox-
icity hampers its clinical applications [50]. The
sensitization of SK-BR-3 cells to TNF-α with anti-HER2
antibodies provides experimental evidence for combin-
ation of low TNF-α doses with anti-HER2 antibody
treatment to achieve effective anti-growth effects. Based
on checkerboard analyses reported in Figure 7, a syner-
gistic anti-growth response could be obtained from SK-
BR-3 cells with as low as 32 U/ml TNF-α under in vitro
conditions. But, one caveat is that the same antibody-
TNF-α combination could produce completely opposite
responses in other cells, as reported here for BT-474 and
MDA-MB-361 cells. For example, as little as 0.1 mg/ml
BH1 antibody was able to abolish TNF-α cytotoxicity in
BT-474 cells.
The mechanisms of differential responses of breast can-
cer cell lines to combined treatment with anti-HER2 anti-
body and TNF-α merit further investigation. Here, we
investigated the mechanisms of growth response of SK-
BR-3 cells to combined treatment. The analysis of several
downstream targets of HER2 signaling indicated that BH1
antibody did not inhibit HER2 phosphorylation, yet it was
able to inhibit the phosphorylation of Akt and ERK1/2
kinases. These changes resulted in a progressive increase
of cyclin D1 protein levels. DNA synthesis was inhibitedand cells accumulated progressively at G1 phase of the cell
cycle. The addition of TNF-α to BH1 treatment dramatic-
ally enhanced these responses leading to an immediate
and stable growth arrest.
Conclusions
Newly generated anti-HER2 monoclonal antibodies allowed
the identification of a novel epitope on HER2 receptor that
is restricted to the intact form of its ECD. These antibodies
displayed cell type-dependent interactions with TNF-α,
resulting in synergistic, antagonistic or independent anti-
growth effects. The synergistic activity was associated with
inhibition of Akt and ERK1/2 phosphorylation leading to
immediate and stable cell cycle arrest.
Additional files
Additional file 1: Anti-HER2 antibodies did not react with EGFR.
Mice were immunized with SK-BR-3 cells, followed by a recombinant
protein composed of extracellular domain of HER2 fused to human IgG1
Fc domain (HER2 ECD). ELISA plates that have been coated with either
HER2 ECD or EGFR ECD were incubated with antibody-containing
hybridoma supernatants, followed by alkaline phosphatase-conjugated
anti-mouse IgG antibodies. The Y axis shows the absorbance (OD)
reading at 405 nm following incubation with alkaline phosphatase
substrate (assays in duplicate).
Additional file 2: Antibody binding to endogenously expressed
HER2 protein as tested by immunoprecipitation-western blot assay.
T47D-derived lysates were subjected to immunoprecipitation with
different anti-HER2 antibodies. Antigen-antibody complexes were
captured onto Protein G-conjugated beads, eluted and subjected to
western blot assay using CB11 antibody. Blots were overexposed to
visualize the weakly positive HER2 immunoprecipitated by BH5 antibody.
Tzm: Trastuzumab used as a positive control antibody. (−): No primary
antibody.
Additional file 3: Epitope mapping of anti-HER2 antibodies using
combined immunoprecipitation-western blot assay. Huh7 cells were
transfected in 6-well plates using a set of mammalian expression
plasmids encoding full-length or N-terminally truncated HER2 protein.
Transfected cells were cultivated for 48 h; cell lysates were subjected to
immunoprecipitation with different anti-HER2 antibodies. Antigen-
antibody complexes were captured onto Protein G-conjugated beads,
eluted and subjected to western blot assay using CB11 antibody. Arrows:
immunoreactive bands specific for full-length and truncated HER2
protein forms. IP: immunoprecipitation; *: non-specific bands originating
from antibodies used for immunoprecipitation.
Additional file 4: Interaction between anti-HER2 antibodies and
tumor necrosis factor-α. MDA-MB-361 cells were partially sensitive to
anti-HER2 antibodies, but highly sensitive to TNF-α (top). MCF-7 cells
were resistant to anti-HER2 antibodies, but highly sensitive to TNF-α
(middle). T47D cells were resistant to both anti-HER2 antibodies and
TNF-α (bottom). Growth measurements observed under 5μg/ml antibody
(white columns), 1000 U/ml TNF-α (striped columns), and 5 μg/ml
antibody + 1000 U/ml TNF-α (black columns) were obtained
experimentally, as described in Figure 6. Growth level under a drug
condition was defined as the growth under that condition normalized by
growth under no drug condition. Expected growth level under no
interaction (gray columns) was calculated by multiplying the growth
levels under each individual drug. The observed growth level for each
combination was divided by the expected growth level to find an
interaction score according to Bliss Independence Model for drug
interactions. Interaction scores were not calculated for these cell lines.
Additional file 5: In vitro molecular responses of SK-BR-3 cells to
tumor necrosis factor-α. SK-BR-3 cells were treated up to 24 h with
Ceran et al. BMC Cancer 2012, 12:450 Page 15 of 16
http://www.biomedcentral.com/1471-2407/12/450TNF-α (1000 U/ml). Cell lysates were prepared from cells harvested at
indicated times (hr, hours) and the expressions of phospho-HER2 (pHER2),
phospho-Akt (pAkt), total Akt (Akt), phospho-ERK1/phospho-Erk2 (pErk1/2),
total Erk1/Erk2 (Erk 1/2) and Cyclin D1 were analyzed by western blotting.
Calnexin was used as a loading control.
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